FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143896607> ?p ?o ?g. }

• W2143896607 endingPage "779" @default.
• W2143896607 startingPage "768" @default.
• W2143896607 abstract "Abstract. The use of non‐steroidal anti‐inflammatory drugs has proved of great interest in the prevention and treatment of colorectal cancer, although their precise mechanisms of action remain unclear. Overexpression of cyclooxygenase‐2 (COX‐2) and subsequent prostaglandin production promote metastasis and have been shown to increase cell motility in vitro . Objective : We have aimed to elucidate whether specific inhibition of COX‐2 with NS‐398 (NS‐398 is a selective inhibitor of COX‐2) would be able to inhibit motility of colorectal cancer cells and whether this was modulated through epidermal growth factor receptor (EGFR) transactivation. Materials and Methods : A transwell filter assay was used to study cell motility. Expression of COX‐2, EGFR phosphorylation and prostaglandin E 2 (PGE 2 ) receptors were assessed by Western blot analysis and reverse transcriptase‐polymerase chain reaction. PGE 2 concentrations after NS‐398 treatment were estimated by enzyme immunoassay. Results : Treatment with NS‐398 significantly reduced PGE 2 levels and reduced cell migration in the HT29 and HCA7 colorectal carcinoma cell lines and this effect was rescued by addition of PGE 2 . Furthermore, specific inhibition of COX‐2 with NS‐398 reduced EGFR phosphorylation in colorectal cancer cells. Direct inhibition of EGFR activity with AG1478 reduced PGE 2 ‐stimulated motility, clearly demonstrating that PGE 2 acts via the EGFR‐signalling pathway. The novel combination of NS‐398 and AG1478 dramatically reduced migration of colorectal cancer cells. Conclusion : The data presented indicate that the use of NS‐398 in chemoprevention and adjuvant therapy for colorectal cancer may work in part, through the inhibition of cell motility. Furthermore, our data suggest that the combined use of non‐steroidal anti‐inflammatory drugs with EGFR antagonists could be explored further for future use in the clinic." @default.
• W2143896607 created "2016-06-24" @default.
• W2143896607 creator A5001995248 @default.
• W2143896607 creator A5028823323 @default.
• W2143896607 creator A5034543758 @default.
• W2143896607 creator A5043839163 @default.
• W2143896607 creator A5049482528 @default.
• W2143896607 creator A5055375263 @default.
• W2143896607 creator A5065031155 @default.
• W2143896607 creator A5087838077 @default.
• W2143896607 date "2007-09-14" @default.
• W2143896607 modified "2023-10-15" @default.
• W2143896607 title "Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy" @default.
• W2143896607 cites W1482218984 @default.
• W2143896607 cites W1685016018 @default.
• W2143896607 cites W180357471 @default.
• W2143896607 cites W1935274862 @default.
• W2143896607 cites W1965536085 @default.
• W2143896607 cites W1965724284 @default.
• W2143896607 cites W1968054887 @default.
• W2143896607 cites W1975204220 @default.
• W2143896607 cites W1977851304 @default.
• W2143896607 cites W2005675676 @default.
• W2143896607 cites W2007180952 @default.
• W2143896607 cites W2008498104 @default.
• W2143896607 cites W2024579029 @default.
• W2143896607 cites W2025006462 @default.
• W2143896607 cites W2033557539 @default.
• W2143896607 cites W2035758011 @default.
• W2143896607 cites W2039281687 @default.
• W2143896607 cites W2048680922 @default.
• W2143896607 cites W2054891808 @default.
• W2143896607 cites W2073738021 @default.
• W2143896607 cites W2076744535 @default.
• W2143896607 cites W2083362070 @default.
• W2143896607 cites W2087744847 @default.
• W2143896607 cites W2097997344 @default.
• W2143896607 cites W2103834391 @default.
• W2143896607 cites W2106293055 @default.
• W2143896607 cites W2112420045 @default.
• W2143896607 cites W2116861117 @default.
• W2143896607 cites W2129733741 @default.
• W2143896607 cites W2132069490 @default.
• W2143896607 cites W2138448256 @default.
• W2143896607 cites W2139629086 @default.
• W2143896607 cites W2143259361 @default.
• W2143896607 cites W2143296984 @default.
• W2143896607 cites W2156470937 @default.
• W2143896607 cites W4237119758 @default.
• W2143896607 cites W4247081510 @default.
• W2143896607 doi "https://doi.org/10.1111/j.1365-2184.2007.00459.x" @default.
• W2143896607 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6496834" @default.
• W2143896607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17877615" @default.
• W2143896607 hasPublicationYear "2007" @default.
• W2143896607 type Work @default.
• W2143896607 sameAs 2143896607 @default.
• W2143896607 citedByCount "36" @default.
• W2143896607 countsByYear W21438966072012 @default.
• W2143896607 countsByYear W21438966072013 @default.
• W2143896607 countsByYear W21438966072014 @default.
• W2143896607 countsByYear W21438966072015 @default.
• W2143896607 countsByYear W21438966072016 @default.
• W2143896607 countsByYear W21438966072017 @default.
• W2143896607 countsByYear W21438966072018 @default.
• W2143896607 countsByYear W21438966072023 @default.
• W2143896607 crossrefType "journal-article" @default.
• W2143896607 hasAuthorship W2143896607A5001995248 @default.
• W2143896607 hasAuthorship W2143896607A5028823323 @default.
• W2143896607 hasAuthorship W2143896607A5034543758 @default.
• W2143896607 hasAuthorship W2143896607A5043839163 @default.
• W2143896607 hasAuthorship W2143896607A5049482528 @default.
• W2143896607 hasAuthorship W2143896607A5055375263 @default.
• W2143896607 hasAuthorship W2143896607A5065031155 @default.
• W2143896607 hasAuthorship W2143896607A5087838077 @default.
• W2143896607 hasBestOaLocation W21438966072 @default.
• W2143896607 hasConcept C104317684 @default.
• W2143896607 hasConcept C121608353 @default.
• W2143896607 hasConcept C126322002 @default.
• W2143896607 hasConcept C1292079 @default.
• W2143896607 hasConcept C170493617 @default.
• W2143896607 hasConcept C185592680 @default.
• W2143896607 hasConcept C2777198256 @default.
• W2143896607 hasConcept C2779013556 @default.
• W2143896607 hasConcept C2779438470 @default.
• W2143896607 hasConcept C2780664492 @default.
• W2143896607 hasConcept C502942594 @default.
• W2143896607 hasConcept C526805850 @default.
• W2143896607 hasConcept C55493867 @default.
• W2143896607 hasConcept C58207958 @default.
• W2143896607 hasConcept C62112901 @default.
• W2143896607 hasConcept C71924100 @default.
• W2143896607 hasConcept C86339819 @default.
• W2143896607 hasConcept C86803240 @default.
• W2143896607 hasConcept C95444343 @default.
• W2143896607 hasConceptScore W2143896607C104317684 @default.
• W2143896607 hasConceptScore W2143896607C121608353 @default.
• W2143896607 hasConceptScore W2143896607C126322002 @default.
• W2143896607 hasConceptScore W2143896607C1292079 @default.

• next